News | October 15, 2010

Medtronic Settles Lawsuits on Defibrillation Leads

October 15, 2010 – Medtronic has entered into a $268 million settlement relating to its Sprint Fidelis family of defibrillation leads.

The leads, which connect implantable electrophysiology devices to the heart, were pulled off the market in October 2007 due to a defect that caused a high rate of lead fractures. The cracked wires in some cases delivered unnecessary shocks or prevented a needed shock from reaching the heart. Lead failure was suspected in about 13 deaths. More than 250,000 Sprint Fidelis leads were implanted in patients prior to the 2007 recall.

Under the terms of the agreement, Medtronic is paying $268 million, which includes attorneys’ fees and administrative expenses. The parties will file joint requests to terminate the multidistrict litigation and Minnesota state court proceedings related to the Sprint Fidelis leads. It will also dismiss the plaintiffs’ appeals pending before the U.S. Court of Appeals for the Eighth Circuit and the Minnesota Court of Appeals and will request dismissal of other Fidelis-related cases throughout the country. Medtronic can cancel the agreement if certain conditions are not met. The agreement can also be terminated by either party if the proceedings are not terminated.

For more information: www.medtronic.com


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now